benzyl 2-(3,4,6-tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl)-α-L-gulopyranosyl-2-oxyethoxy)ethylcarbamate | 1266609-55-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: benzyl 2-(3,4,6-tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl)-α-L-gulopyranosyl-2-oxyethoxy)ethylcarbamate
• 英文别名: 2-[2-(benzyloxycarbonylamino)ethyloxy]ethyl 3,4,6-tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-(carbamoyl)-α-D-mannopyranosyl)-α-L-gulopyranoside；(2R,3R,4S,5S,6R)-2-(acetoxymethyl)-4-(carbamoyloxy)-6-(((2R,3S,4S,5R,6S)-4,5-diacetoxy-6-(acetoxymethyl)-2-(2-(2-(((benzyloxy)carbonyl)amino)ethoxy)ethoxy)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-3,5-diyl diacetate；2-[2-(benzyloxycarbonylamino)ethyloxy]ethyl 3,4,6-tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-(carbamoyl)-alpha-D-mannopyranosyl)-alpha-L-gulopyranoside；(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-4-(carbamoyloxy)-6-((2R,3S,4S,5S,6S)-4,5-diacetoxy-6-(acetoxymethyl)-2-(2-(2-(benzyloxycarbonylamino)ethoxy)ethoxy)tetrahydro-2H-pyran-3-yloxy)tetrahydro-2H-pyran-3,5-diyl diacetate；[(2S,3R,4S,5S,6R)-3,4-diacetyloxy-5-[(2R,3S,4S,5R,6R)-3,5-diacetyloxy-6-(acetyloxymethyl)-4-carbamoyloxyoxan-2-yl]oxy-6-[2-[2-(phenylmethoxycarbonylamino)ethoxy]ethoxy]oxan-2-yl]methyl acetate
• CAS: 1266609-55-5
• 化学式: C₃₇H₅₀N₂O₂₁
• 分子量: 858.805
• InChiKey: GXJQFMILDMNGIF-JTPVZCPOSA-N

物化性质

• 沸点：
  882.9±65.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  60
• 可旋转键数：
  28
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  295
• 氢给体数：
  2
• 氢受体数：
  21

反应信息

• 作为反应物：
  描述：

  benzyl 2-(3,4,6-tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl)-α-L-gulopyranosyl-2-oxyethoxy)ethylcarbamate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  博莱霉素（BLM）碳水化合物部分的多克级合成：探索与10-羟基喜树碱（10-HCPT）相连的BLM二糖的抗肿瘤有益作用†

  摘要：

  博来霉素（BLM）二糖的“寻找肿瘤”作用已被证明可作为癌症诊断的有前途的工具和靶向治疗的潜在配体。然而，缺乏BLM二糖常常阻碍了这些实际应用。在此，通过TMSOTF介导的糖苷偶联方式，以苄基半乳糖苷的总收率为43.6％，有效地完成了全乙酰化的BLM二糖20的多克合成。合成策略的关键创新在于，首先采用廉价的苄基半乳糖苷来制备L-葡萄糖亚基3作为糖基受体，其路线要短得多，产率为73.0％，而3 - O-氨基甲酰基-甘露糖供体4通过降低二丁基氧化锡的量，并将氨解和选择性脱乙酰基合并为一锅法反应，可实现47.2％的收率。接下来，将BLM二糖掺入非特异性模型化合物10-羟基喜树碱（10-HCPT）中以形成缀合物1，与10-HCPT相比，可以显着提高抗肿瘤活性并表现出对癌细胞和正常细胞的明显选择性。此外，BLM双糖本身无细胞毒性，清楚地表明了BLM双糖在解决针对细胞毒药物的靶向抗肿瘤治疗中的重要性和潜力。

  DOI：

  10.1039/c8nj06191b
• 作为产物：
  描述：

  1,2,4,6-tetra-O-acetyl-α-D-mannopyranose 在 4-二甲氨基吡啶 、 正丁基锂 、 三氟甲磺酸三甲基硅酯 、 硫酸 、 palladium on activated charcoal 、 氨 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 16.84h， 生成 benzyl 2-(3,4,6-tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl)-α-L-gulopyranosyl-2-oxyethoxy)ethylcarbamate
  参考文献：
  名称：

  博莱霉素（BLM）碳水化合物部分的多克级合成：探索与10-羟基喜树碱（10-HCPT）相连的BLM二糖的抗肿瘤有益作用†

  摘要：

  博来霉素（BLM）二糖的“寻找肿瘤”作用已被证明可作为癌症诊断的有前途的工具和靶向治疗的潜在配体。然而，缺乏BLM二糖常常阻碍了这些实际应用。在此，通过TMSOTF介导的糖苷偶联方式，以苄基半乳糖苷的总收率为43.6％，有效地完成了全乙酰化的BLM二糖20的多克合成。合成策略的关键创新在于，首先采用廉价的苄基半乳糖苷来制备L-葡萄糖亚基3作为糖基受体，其路线要短得多，产率为73.0％，而3 - O-氨基甲酰基-甘露糖供体4通过降低二丁基氧化锡的量，并将氨解和选择性脱乙酰基合并为一锅法反应，可实现47.2％的收率。接下来，将BLM二糖掺入非特异性模型化合物10-羟基喜树碱（10-HCPT）中以形成缀合物1，与10-HCPT相比，可以显着提高抗肿瘤活性并表现出对癌细胞和正常细胞的明显选择性。此外，BLM双糖本身无细胞毒性，清楚地表明了BLM双糖在解决针对细胞毒药物的靶向抗肿瘤治疗中的重要性和潜力。

  DOI：

  10.1039/c8nj06191b

文献信息

• Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation
  作者：Maolin Li、Wenchong Ye、Kaishuo Fu、Cui zhou、Yonghui Shi、Weiping Huang、Wenming Chen、Jiliang Hu、Zhilin Jiang、Wen Zhou

  DOI：10.1016/j.ejmech.2020.112509

  日期：2020.9

  Thirty novel 20 (S)-O-linked camptothecin (CPT) glycoconjugates were synthesized. They showed more potent in vitro cytotoxicities over irinotecan, but very weak direct topoisomerase I (Topo I) inhibition was observed at 100.0 μM. Oligosaccharide types, length of a PEG linker and acetyl groups exerted obvious effects on cytotoxicity, selectivity, water solubility and stability of the newly synthesized

  合成了三十种新颖的20（S）-O-连接的喜树碱（CPT）糖缀合物。他们表现出更有效的体外细胞毒性过伊立替康，但非常弱的直接拓扑异构酶I在100.0观察（TOPO I）抑制μ M.寡糖类型，PEG接头的长度和乙酰基作用于细胞毒性，选择性，水溶性明显影响，并新合成的CPT糖缀合物的稳定性。结构40与CPT相比，博来霉素（BLM）二糖与引入的酯部分中的二甘醇相连，具有更高的抗肿瘤活性和独特的选择性。静脉内动物急性毒性（160 mg / kg）未检测到毒性。总的来说，将具有靶向肿瘤的寡糖附着到CPT的20（S）-OH上可以为当前的Topo I毒药带来的艰巨问题提供解决方案。
• [EN] CARBOHYDRATE-MEDIATED TUMOR TARGETING<br/>[FR] CIBLAGE DE TUMEURS MÉDIÉ PAR UN HYDRATE DE CARBONE
  申请人：UNIV ARIZONA

  公开号：WO2011019419A1

  公开（公告）日：2011-02-17

  Tumors can be selectively targeted via compounds provided herein according to the formula, or a pharmaceutically acceptable salt thereof, wherein RA and RB are as defined herein. Tumors can be imaged or targeted for therapeutic treatment using compounds described herein where at least one RA or at least one RB group comprises a imaging agent, a therapeutic agent, or a member of a specific binding pair which can be associated with a secondary imaging agent, such as a microbubble for ultrasonic imaging.

  本文提供的化合物可选择性地针对肿瘤，其中根据以下公式或其药用可接受的盐，其中RA和RB如本文所定义。肿瘤可通过本文描述的化合物进行成像或靶向治疗，其中至少一个RA或至少一个RB基团包含成像剂、治疗剂或特定结合对的成员，可与次级成像剂（如用于超声成像的微泡）结合。
• Selective Tumor Cell Targeting by the Disaccharide Moiety of Bleomycin
  作者：Zhiqiang Yu、Ryan M. Schmaltz、Trevor C. Bozeman、Rakesh Paul、Michael J. Rishel、Krystal S. Tsosie、Sidney M. Hecht

  DOI：10.1021/ja311090e

  日期：2013.2.27

  In a recent study, the well-documented tumor targeting properties of the antitumor agent bleomycin (BLM) were studied in cell culture using microbubbles that had been derivatized with multiple copies of BLM. It was shown that BLM selectively targeted MCF-7 human breast carcinoma cells but not the "normal" breast cell line MCF-10A. Furthermore, it was found that the BLM analogue deglycobleomycin, which lacks the disaccharide moiety of BLM, did not target either cell line, indicating that the BLM disaccharide moiety is necessary for tumor selectivity. Not resolved in the earlier study were the issues of whether the BLM disaccharide moiety alone is sufficient for tumor cell targeting and the possible cellular uptake of the disaccharide. In the present study, we conjugated BLM, deglycoBLM, and BLM disaccharide to the cyanine dye Cy5**. It was found that the BLM and BLM disaccharide conjugates, but not the deglycoBLM conjugate, bound selectively to MCF-7 cells and were internalized. The same was also true for the prostate cancer cell line DU-145 (but not for normal PZ-HPV-7 prostate cells) and for the pancreatic cancer cell line BxPC-3 (but not for normal SVR A221a pancreas cells). The targeting efficiency of the disaccharide was only slightly less than that of BLM in MCF-7 and DU-145 cells and comparable to that of BLM in BxPC-3 cells. These results establish that the BLM disaccharide is both necessary and sufficient for tumor cell targeting, a finding with obvious implications for the design of novel tumor imaging and therapeutic agents.